Vancomycin: The need to suit serum concentrations in hemodialysis patients

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 2, 2010, Pages 203-208

  Marengo, Lívia Luize ^a   del Fiol, Fernando de Sá ^a   de Jesus Oliveira, Sara ^a   Nakagawa, Celso ^b   Croco, Eduardo Leite ^b   Barberato Filho, Silvio ^a   Peçanha, Marcela ^c   da Silva, Douglas Felix ^a   de Toledo, Maria Inês ^a,d  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b Secretaria da Saúde do Estado de São Paulo   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d Faculdade de Tecnologia de Sorocaba   (Brazil)

Author keywords

Chronic renal failure; Hemodialysis; Vancomycin

Indexed keywords

ALBUMIN; OXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BLOOD SAMPLING; BRAZIL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOFLUORESCENCE; MALE; STAPHYLOCOCCUS AUREUS; BLOOD; DRUG MONITORING; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TIME;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; VANCOMYCIN;

EID: 77954771709     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1413-8670(10)70041-6     Document Type: Article

References (28)

1. Klasco RK editor. Martindale: the extra pharmacopoeia. Base de dados na Internet. Greenwood Village: Thomson MICROMEDEX; 1974-2006. Disponível: http://www.periodicos.capes. gov.br. Acesso em 20 de maio de 2008.
2. Ge M, Chen Z, Onishi HR, Kohler J, Silver LL et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-ala-D-ala. Science 1999; 284:507-510.
3. Marinho, DS Vancomicina, estudo de utilização com ênfase em suas reações adversas. 2005. 120 f. Dissertação (Mestrado)-Fundação Oswaldo Cruz, Rio de Janeiro, 2005.
4. Bartlett JG Antibiotic selection for infections involving methicillin-resistant Staphylococcus aureus. 2004. Disponível em: http://www.medscape.com/viewprogram/3124. Acesso em 03 de dezembro 2007.
5. Lentino JR, Leehey DJ. Infecções.Daugirdas JT, Blake PG, Ing TS. Manual de diálise. 3. ed. Rio de Janeiro: Guanabara Koogan, 2001.
6. Marcondes CRR, Biojone CR, Cherri JM, Takachi P, Carlos E. Complicações precoces e tardias em acesso venoso central: análise de 66 implantes. Acta Cirúrgica Brasileira 2007; 15:73-75.
7. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clinical Nephrology 2003; 60:96-104.
8. Silva LAM, Pansard HM, Rosa DB, Botton SR, Mezzomo NF et al. Níveis sanguíneos de vancomicina e adequação de seu uso em pacientes com insuficiência renal em tratamento dialítico. Jornal Brasileiro de Nefrologia 1998; 20:411-418.
9. Tavares W. Glicopeptídeos e Lipopeptídeos. In: Antibióticos e quimioterápicos para o clínico. São Paulo: Atheneu, 2007.
10. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Critical Care 2002; 6(4):313-316.
11. Livornese LL, Slavin D, Gilbert B, Robbins P, Santoro J. Use of antimicrobial agents in renal failure. Infectious Disease Clinics of North America 2004; 18(3):551-579.
12. Bingen E, Mariani-Kurkdjian P, Nebbad B. Optimal vancomycin serum level in Staphylococcus aureus infections? Medecine et Maladies Infectieuses 2006; 36(9):439-442.
13. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett ́s: principles and pratice of infectious diseases. 6 ed. Philadelfi a: Elsevier, 2005.
14. Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA et al. Use of vancomycin or fi rst-generation cephalosporins for the treatment of hemodialisys-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2007; 20:190-196.
15. Nielsen HE, Hansen HE, Korsager B, Skov PE. Renal excretion of vancomycin in kidney disease. Acta Medica Scandinavica 1975; 197(4):261-264.
16. Masur H, Francioli P, Ruddy M, Murray HW. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clinical Nephrology 1993; 2:85-88.
17. Gonzalez-Martin G, Acuna V, Perez C, Labarca J, Guevara A, Tagle R. Pharmacokinetics of vancomycin in patients with severely impaired renal function. International Journal of Clinical Pharmacology and Therapeutics 1996; 34(2): 71-75.
18. Zoer J, Schrander-Van Der Meer AM, Van Dorp WT. Dosage recommendations of vancomycin during haemodialysis with highly permeable membranes. Pharmacy World & Science 1997; 19(4):191-196.
19. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered high fl ux hemodialysis. Clinical Nephrology 1998; 50(1):51-55.
20. Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM. CAHP-210 dialyzer infl uence on intra-dialytic vancomycinvancomycin removal. Nephrology Dialysis Transplantation 2002; 17(9):1649-1654.
21. Goldman L, Ausiello D. Cecil: tratado de medicina interna. 22. ed. Rio de Janeiro: Elsevier, 2005.
22. Bernardes RC, Jorge AOC, Leão MVP. Sensibilidade à oxacilina, vancomicina e teicoplanina de Staphylococcus coagulasepositivo isolados de pacientes hospitalizados de São José dos Campos. Revista Biociências 2004; 10(1-2):73-78.
23. Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus infererence to accessory gene regulator (agr) polymorphism and function. Journal of Antimicrobial Chemotherapy 2007; 59:1190-1193.
24. Sakoulas G, Howard SG, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. Journal of Antimicrobial Chemotherapy 2006; 57(4):699-704.
25. Johnson AP, Woodford N. Glycopeptide-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 2002; 50:621-623.
26. Center for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance. 1998; 48:1167-1171.
27. Finch RG, Eliopoulos GM. Safety and effi cacy glicopeptide antibiotics. Journal of Antimicrobial Chemotherapy 2005; 55(S2):ii5-ii13.
28. Santos CR, Feferbaum R, Paula LSA, Bertoline MA, Omosako CEK, Santos SRC. Micrométodo para quantifi cação da vancomicina em plasma através da cromatografi a líquida de alta eficiência: monitorização plasmática de vancomicina na sustentação farmacológica de neonatos com sepse. Revista Brasileira de Ciências Farmacêuticas 2001; 37(1):87-93.